[go: up one dir, main page]

MX2013013734A - Familia de carba-azucares de arilo, heteroarilo, o-arilo y o-heteroarilo. - Google Patents

Familia de carba-azucares de arilo, heteroarilo, o-arilo y o-heteroarilo.

Info

Publication number
MX2013013734A
MX2013013734A MX2013013734A MX2013013734A MX2013013734A MX 2013013734 A MX2013013734 A MX 2013013734A MX 2013013734 A MX2013013734 A MX 2013013734A MX 2013013734 A MX2013013734 A MX 2013013734A MX 2013013734 A MX2013013734 A MX 2013013734A
Authority
MX
Mexico
Prior art keywords
heteroaryl
aryl
diabetes
skin
well
Prior art date
Application number
MX2013013734A
Other languages
English (en)
Inventor
Géraldine Deliencourt-Godefroy
Lénaïg Lopes
Original Assignee
Tfchem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tfchem filed Critical Tfchem
Publication of MX2013013734A publication Critical patent/MX2013013734A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/247—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/29—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/09—Preparation of ethers by dehydration of compounds containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/22—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogens; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/24—Preparation of ethers by reactions not forming ether-oxygen bonds by elimination of halogens, e.g. elimination of HCl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/235—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C43/253—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring other than a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

Se describe un compuesto de la siguiente fórmula (I): así como su proceso de preparación, una composición farmacéutica y cosmética que lo comprende y el uso de las mismas, particularmente como un inhibidor del co- transportador de glucosa dependiente de sodio, tal como SGLT1, SGLT2 y SGLT3, en particular en el tratamiento o prevención de la diabetes, y más particularmente la diabetes tipo II, las complicaciones relacionadas con la diabetes, tales como arteritis de las extremidades inferiores, infarto cardiaco, insuficiencia renal, neuropatía o ceguera, hiperglucemia, hiperinsulinemia, obesidad, hipertrigliceridemia, síndrome X y arterioesclerosis, así como para uso como fármaco anti-cancerígeno, anti-infeccioso, anti-viral, anti-trombótico o anti-inflamatorio, o para abrillantar, blanquear, decolorar la piel, quitar las manchas de la piel, particularmente las pecas y manchas de la edad, o prevenir la pigmentación de la piel.
MX2013013734A 2011-05-26 2012-05-29 Familia de carba-azucares de arilo, heteroarilo, o-arilo y o-heteroarilo. MX2013013734A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305645 2011-05-26
PCT/EP2012/060050 WO2012160218A1 (en) 2011-05-26 2012-05-29 Family of aryl, heteroaryl, o-aryl and o-heteroaryl carbasugars

Publications (1)

Publication Number Publication Date
MX2013013734A true MX2013013734A (es) 2014-02-27

Family

ID=46262085

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013013734A MX2013013734A (es) 2011-05-26 2012-05-29 Familia de carba-azucares de arilo, heteroarilo, o-arilo y o-heteroarilo.

Country Status (16)

Country Link
US (1) US9434670B2 (es)
EP (1) EP2714636B9 (es)
JP (1) JP5844888B2 (es)
KR (1) KR101961884B1 (es)
CN (2) CN104909997B (es)
AP (1) AP3308A (es)
AU (1) AU2012260741B2 (es)
BR (1) BR112013030163A2 (es)
CA (1) CA2835755C (es)
IL (1) IL229581A (es)
MX (1) MX2013013734A (es)
PH (1) PH12013502352B1 (es)
RU (1) RU2603769C2 (es)
SG (1) SG194954A1 (es)
WO (1) WO2012160218A1 (es)
ZA (1) ZA201308878B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
CN104341358B (zh) * 2013-07-25 2016-05-18 昆药集团股份有限公司 一种化合物及其制备方法与应用
CN104418834B (zh) * 2013-08-23 2017-09-15 重庆博腾制药科技股份有限公司 一种抗糖尿病药物中间体的合成方法
EP3089969A2 (en) * 2014-01-03 2016-11-09 Elexopharm GmbH Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
EP2918579A1 (en) 2014-03-14 2015-09-16 LEK Pharmaceuticals d.d. Synthesis of 2-arylmethyl-5-aryl-thiophene
CN103980263B (zh) * 2014-04-17 2016-08-03 海门瑞一医药科技有限公司 卡格列净的合成工艺
CN105017351B (zh) * 2014-04-18 2017-10-20 杭州师范大学 一种糖基吡唑类化合物及其制备和应用
US9695159B2 (en) * 2014-05-27 2017-07-04 Glenmark Pharmaceuticals Limited Process for preparation of canagliflozin
CN104086523A (zh) * 2014-06-09 2014-10-08 上海方楠生物科技有限公司 一种制备坎格列净中间体2-(4-氟苯基)-5-[(5-卤代-2-甲基苯基)甲基]噻吩的方法
CN105272960A (zh) 2014-07-18 2016-01-27 上海科胜药物研发有限公司 一种坎格列净中间体2-(2-甲基-5-溴苄基)-5-(4-氟苯)噻吩的制备方法
CN104672207B (zh) * 2015-02-11 2016-06-01 佛山市赛维斯医药科技有限公司 一种硝基噻吩酰胺甲苯类双靶点抑制剂及其用途
WO2016139501A1 (en) * 2015-03-04 2016-09-09 Tfchem Gem difluorocompounds as depigmenting or lightening agents
CN106365966A (zh) * 2015-07-24 2017-02-01 上海医药集团股份有限公司 一种苄基芳基醚的制备方法
CN105461680B (zh) * 2015-12-29 2018-06-22 苏州毕奇尔生物科技有限公司 一种2-(4-氟苯基)噻吩的合成方法
WO2018037254A1 (en) * 2016-08-24 2018-03-01 Tfchem Difluorinated compounds as depigmenting or lightening agents
JP6812327B2 (ja) * 2017-11-21 2021-01-13 株式会社日立製作所 治療選択支援システム及び方法
CN110950833A (zh) * 2019-12-11 2020-04-03 台州学院 一种2-(4-氟苯基)-5-[(5-溴-2-甲基苯基)甲基]噻吩的制备方法
CN116535295A (zh) * 2022-01-26 2023-08-04 江苏万邦生化医药集团有限责任公司 一种sglt2抑制剂中间体v的制备方法
CN116535299A (zh) * 2022-01-26 2023-08-04 江苏万邦生化医药集团有限责任公司 一种sglt2抑制剂中间体v-1及其应用
CN116785268A (zh) * 2022-03-14 2023-09-22 江苏万邦生化医药集团有限责任公司 一种sglt-2抑制剂的药物组合物
CN119110722A (zh) 2022-05-25 2024-12-10 勃林格殷格翰动物保健有限公司 包含sglt-2抑制剂的水性医药组合物
AR132054A1 (es) 2023-03-06 2025-05-21 Boehringer Ingelheim Vetmedica Gmbh Sistemas y métodos para la administración de composiciones farmacéuticas líquidas, en particular que comprenden uno o más inhibidores de sglt-2
TW202508455A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
CN121218995A (zh) 2023-05-24 2025-12-26 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及匹莫苯丹和/或替米沙坦的非人类哺乳动物中心脏疾病的组合治疗和/或预防
CN117800819B (zh) * 2023-12-18 2025-08-15 浙江大学衢州研究院 一种铜基催化剂催化2,3-丁二醇选择性脱氢制备乙偶姻的方法
WO2025245592A1 (en) * 2024-05-31 2025-12-04 Aché Laboratórios Farmacêuticos S.A. Multi-target compounds, process for the preparation of the compounds, intermediates, pharmaceutical composition, pharmaceutically acceptable salts, combination, medicament, use of a compound and method of treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335894C (en) 1986-03-05 1995-06-13 Hiroshi Fukase Inosose derivatives and production thereof
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
JP2007509963A (ja) * 2003-10-30 2007-04-19 メルク　エンド　カムパニー　インコーポレーテッド 抗高コレステロール血漿薬としての２−アゼチジノン
DE102004058449A1 (de) * 2004-12-03 2006-06-14 Merck Patent Gmbh Tetrahydropyranderivate
AU2007329490B2 (en) * 2006-12-04 2012-05-17 Janssen Pharmaceutica N.V. Thienyl-containing glycopyranosyl derivatives as antidiabetics
UA101004C2 (en) * 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
JP5258327B2 (ja) 2008-02-28 2013-08-07 東ソー株式会社 ポリイソシアネートの製造方法
FR2929615B1 (fr) 2008-04-02 2010-12-17 Tfchem Composes c-aryl glycosides pour le traitement du diabete et de l'obesite.
US20100167989A1 (en) * 2008-10-23 2010-07-01 Auspex Pharmaceuticals, Inc. Isopropoxyphenylmethyl inhibitors of sglt2

Also Published As

Publication number Publication date
EP2714636B1 (en) 2015-12-16
CN104909997A (zh) 2015-09-16
US9434670B2 (en) 2016-09-06
ZA201308878B (en) 2015-02-25
JP2014520091A (ja) 2014-08-21
NZ618098A (en) 2015-07-31
EP2714636B9 (en) 2017-03-22
IL229581A (en) 2017-02-28
US20140105839A1 (en) 2014-04-17
AP2013007322A0 (en) 2013-12-31
AU2012260741B2 (en) 2016-10-27
WO2012160218A1 (en) 2012-11-29
BR112013030163A2 (pt) 2017-03-01
CN104909997B (zh) 2017-04-12
IL229581A0 (en) 2014-01-30
SG194954A1 (en) 2013-12-30
AU2012260741A1 (en) 2013-12-12
PH12013502352B1 (en) 2019-01-16
CA2835755A1 (en) 2012-11-29
EP2714636A1 (en) 2014-04-09
KR20140053914A (ko) 2014-05-08
PH12013502352A1 (en) 2014-01-06
CN103649033A (zh) 2014-03-19
RU2603769C2 (ru) 2016-11-27
AP3308A (en) 2015-06-30
CN103649033B (zh) 2016-02-24
KR101961884B1 (ko) 2019-03-25
RU2013154353A (ru) 2015-07-10
JP5844888B2 (ja) 2016-01-20
CA2835755C (en) 2019-07-02

Similar Documents

Publication Publication Date Title
PH12013502352B1 (en) Family of aryl, heteroaryl, o-aryl and o-heteroaryl carbasugars
WO2011159067A3 (en) Thiazole derivatives as sglt2 inhibitors and pharmaceutical composition comprising same
IL219309A (en) History of glycoside, including pharmaceutical preparations and their use in the preparation of diabetes medications
PH12013500809A1 (en) Pharmaceutical composition, methods for treating and uses thereof
NO20085056L (no) Insulinderivat
PH12013500473A1 (en) Triazine-oxadiazoles
WO2008042688A3 (en) Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
UA96441C2 (ru) Фармацевтическая композиция, которая содержит аналог тиазолидиндиона митоглитазон, для лечения заболеваний, опосредованных метаболическим воспалением
NO20082538L (no) Stabiliserte lantankarbonatsammensetninger
BR112014010206B8 (pt) composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
IN2012DN02139A (es)
WO2012163928A3 (en) Topical wash composition for use in acne patients
WO2011048148A3 (en) Glycoside derivative and uses thereof
WO2012108677A3 (ko) 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
WO2007121352A3 (en) Therapeutic triterpenoids
GEP20115342B (en) New diosmetin derivatives, process for their preparation and pharmaceutical compositions containing them
WO2007097989A3 (en) A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
WO2018169282A3 (ko) Atpif1을 함유하는 당뇨 치료용 약학조성물
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
GEP20135832B (en) Benzothiazines derivatives, preparation thereof, and their application as drugs
WO2010056527A3 (en) B-biphenyl sulfonamide compounds as ion channel modulators
WO2012033390A3 (en) Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same
MX2011013130A (es) Nuevos compuestos de bencensulfonamida, metodo para sintetizarlos y su utilizacion en medicina asi como tambien en cosmeticos.
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use